First produced in 2006 from mouse cells and in 2007 from human cells, induced pluripotent stem cells (iPSCs) are recognized by many both within and beyond the scientific community as a breakthrough, game-changing development in stem cell biology.
As with any new technology, the challenges are many, including loq rates of reprogramming and control of reprogramming factor expression. To meet the challenges of induced pluripotency, Sigma has partnered with Stemgent® Inc to provide the highest quality reprogramming lentiviruses available and expert technical support.